{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:35:03Z","timestamp":1776332103483,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.4158\/ep14464.dsc","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T17:56:43Z","timestamp":1431367003000},"page":"534-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Aace\/Ace Disease State Clinical Review: Diagnosis and Management of Midgut Carcinoids"],"prefix":"10.1016","volume":"21","author":[{"given":"Eric H.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen C.","family":"Solorzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Katznelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP14464.DSC_bb0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0889-8553(21)00446-5","article-title":"Clinical features, diagnosis, and localization of carcinoid tumors and their management","volume":"18","author":"Vinik","year":"1989","journal-title":"Gastroenterol Clin North Am"},{"key":"10.4158\/EP14464.DSC_bb0015","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"10.4158\/EP14464.DSC_bb0020","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP14464.DSC_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.4158\/EP14464.DSC_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP14464.DSC_bb0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS consensus guidelines for the diagnosis of neuroendocrine tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-9343(87)90422-0","article-title":"Carcinoids and carcinoid syndrome","volume":"82","author":"Creutzfeldt","year":"1987","journal-title":"Am J Med"},{"key":"10.4158\/EP14464.DSC_bb0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/pgmj.71.839.542","article-title":"The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid","volume":"71","author":"Tormey","year":"1995","journal-title":"Postgrad Med J"},{"key":"10.4158\/EP14464.DSC_bb0050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"key":"10.4158\/EP14464.DSC_bb0055","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1054\/bjoc.2000.1659","article-title":"A new human chromogranin \u2018A\u2019 immunoradiometric assay for the diagnosis of neuroendocrine tumours","volume":"84","author":"Bernini","year":"2001","journal-title":"Br J Cancer"},{"key":"10.4158\/EP14464.DSC_bb0060","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1470::AID-CNCR7>3.0.CO;2-S","article-title":"Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas","volume":"85","author":"Goebel","year":"1999","journal-title":"Cancer"},{"key":"10.4158\/EP14464.DSC_bb0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1245\/s10434-006-9148-z","article-title":"Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors","volume":"14","author":"Jensen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.4158\/EP14464.DSC_bb0070","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ajcn\/42.4.639","article-title":"Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid","volume":"42","author":"Feldman","year":"1985","journal-title":"Am J Clin Nutr"},{"key":"10.4158\/EP14464.DSC_bb0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1258\/acb.2008.008033","article-title":"A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours","volume":"45","author":"Stronge","year":"2008","journal-title":"Ann Clin Biochem"},{"key":"10.4158\/EP14464.DSC_bb0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MPA.0b013e3181c68d7a","article-title":"Development of a highly sensitive and specific carboxyterminal human pancreastatin assay to monitor neuroendocrine tumor behavior","volume":"39","author":"O'Dorisio","year":"2010","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0085","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1136\/gut.2006.092320","article-title":"Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours","volume":"55","author":"Turner","year":"2006","journal-title":"Gut"},{"key":"10.4158\/EP14464.DSC_bb0090","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/MPA.0b013e318232b6a2","article-title":"Validation of neurokinin a assays in the United States and Europe","volume":"40","author":"Mamikunian","year":"2011","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MPA.0b013e3181bc0e77","article-title":"Biochemical testing for neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000184855","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations","volume":"90","author":"Sundin","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP14464.DSC_bb0105","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00261-003-0162-3","article-title":"Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS","volume":"29","author":"Kumbasar","year":"2004","journal-title":"Abdom Imaging"},{"key":"10.4158\/EP14464.DSC_bb0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP14464.DSC_bb0115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastroentero-pancreatic tumours","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.4158\/EP14464.DSC_bb0120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTATyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"key":"10.4158\/EP14464.DSC_bb0125","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14464.DSC_bb0130","series-title":"WHO Classification of Tumours of the Digestive System","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","author":"Rindi G","year":"2010"},{"key":"10.4158\/EP14464.DSC_bb0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","article-title":"Surgical treatment of advanced-stage carcinoid tumors: lessons learned","volume":"241","author":"Boudreaux","year":"2005","journal-title":"Ann Surg"},{"key":"10.4158\/EP14464.DSC_bb0145","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"key":"10.4158\/EP14464.DSC_bb0150","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","article-title":"Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center","volume":"36","author":"Norl\u00e9n","year":"2012","journal-title":"World J Surg"},{"key":"10.4158\/EP14464.DSC_bb0155","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"key":"10.4158\/EP14464.DSC_bb0160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.surg.2008.06.008","article-title":"The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors","volume":"144","author":"Chambers","year":"2008","journal-title":"Surgery"},{"key":"10.4158\/EP14464.DSC_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.4158\/EP14464.DSC_bb0170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14464.DSC_bb0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.4158\/EP14464.DSC_bb0180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14464.DSC_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Alimen Pharmacol Ther"},{"key":"10.4158\/EP14464.DSC_bb0190","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.4158\/EP14464.DSC_bb0195","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP14464.DSC_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/1471-2407-13-427","article-title":"Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study","volume":"13","author":"Martin-Richard","year":"2013","journal-title":"BMC Cancer"},{"key":"10.4158\/EP14464.DSC_bb0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"10.4158\/EP14464.DSC_bb0210","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.4158\/EP14464.DSC_bb0215","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.4158\/EP14464.DSC_bb0220","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14464.DSC_bb0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11102-013-0478-0","article-title":"Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study","volume":"17","author":"Petersenn","year":"2014","journal-title":"Pituitary"},{"key":"10.4158\/EP14464.DSC_bb0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP14464.DSC_bb0235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-013-2202-1","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study","volume":"72","author":"Wolin","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.4158\/EP14464.DSC_bb0240","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1301537","article-title":"Ondansetron for diarrhea associated with neuroendocrine tumors","volume":"368","author":"Kiesewetter","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14464.DSC_bb0245","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.4158\/EP14464.DSC_bb0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000225951","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs","volume":"90","author":"Kwekkeboom","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP14464.DSC_bb0255","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPA.0b013e31819b6441","article-title":"Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:21Z","timestamp":1761515901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20356500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1530891X20356500"],"URL":"https:\/\/doi.org\/10.4158\/ep14464.dsc","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aace\/Ace Disease State Clinical Review: Diagnosis and Management of Midgut Carcinoids","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP14464.DSC","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}